IL263174A - Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases - Google Patents

Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases

Info

Publication number
IL263174A
IL263174A IL263174A IL26317418A IL263174A IL 263174 A IL263174 A IL 263174A IL 263174 A IL263174 A IL 263174A IL 26317418 A IL26317418 A IL 26317418A IL 263174 A IL263174 A IL 263174A
Authority
IL
Israel
Prior art keywords
cannabidiol
compositions
hyaluronic acid
treating inflammatory
joint diseases
Prior art date
Application number
IL263174A
Other languages
Hebrew (he)
Inventor
Tamir Gedo
Original Assignee
Tamir Gedo
Bol Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tamir Gedo, Bol Pharma Ltd filed Critical Tamir Gedo
Publication of IL263174A publication Critical patent/IL263174A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL263174A 2016-05-24 2018-11-21 Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases IL263174A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340576P 2016-05-24 2016-05-24
PCT/IL2017/050580 WO2017203529A1 (en) 2016-05-24 2017-05-24 Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases

Publications (1)

Publication Number Publication Date
IL263174A true IL263174A (en) 2018-12-31

Family

ID=60411168

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263174A IL263174A (en) 2016-05-24 2018-11-21 Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases

Country Status (4)

Country Link
EP (1) EP3463304A4 (en)
CA (1) CA3025208A1 (en)
IL (1) IL263174A (en)
WO (1) WO2017203529A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
AU2019299213A1 (en) * 2018-07-02 2021-02-11 Companion Sciences, Llc Cannabidiol combination compositions
WO2020021545A1 (en) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol and glucosamine for treating inflammatory joint diseases
WO2020024056A1 (en) * 2018-08-01 2020-02-06 Lazar Eve Compositions comprising cannabinoids and absorbable material and uses thereof
JP2022502471A (en) * 2018-10-10 2022-01-11 ティルレイ，インコーポレイティド Methods and formulations for treating chemotherapy-induced nausea and vomiting
MX2021006912A (en) * 2018-12-11 2021-08-24 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof.
EP3935036A1 (en) * 2019-03-05 2022-01-12 Colleen Smith Veterinary compositions and methods of use therefor
US20200352849A1 (en) * 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
IT201900008409A1 (en) * 2019-06-07 2020-12-07 Vivatis Pharma Gmbh Identification and selection of a vegetable starting material of chondroitin sulfate and vegetable hyaluronic acid, and transformation of this vegetable starting material to obtain ingredients for use in foods, supplements, medical devices or drugs
JP2022550797A (en) * 2019-10-03 2022-12-05 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド Liposomal cannabinoids and their uses
WO2021091905A1 (en) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Liposomal formulations for delivery of cannabinoids and methods of making thereof
JP2023510089A (en) * 2019-12-13 2023-03-13 フォリウムラボ インコーポレーティッド Complexes Comprising Carbohydrate Polymers and Active Ingredients and Methods for Their Preparation
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
EP3861996A1 (en) 2020-02-04 2021-08-11 I+Med S. Coop. Controlled release system of phytocannabinoids formulations soluble in aqueous media, methods and uses thereof
CN112138138B (en) * 2020-11-19 2023-05-23 乐康珍泰（天津）生物技术有限公司 Pharmaceutical composition for treating gout and preparation method thereof
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
CA3217973A1 (en) * 2021-05-03 2022-11-10 Donald L. Simmons Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof
IT202200002000A1 (en) * 2022-02-04 2023-08-04 Mak Pharma S R L Liposomal oral composition of at least one active ingredient that is poorly absorbable at the intestinal level

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
PT2176208E (en) * 2007-07-30 2015-05-11 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
EP2227085A4 (en) * 2007-12-06 2013-10-09 Berg Pharma Llc Inhalable compositions having enhanced bioavailability
TWI382841B (en) * 2010-10-29 2013-01-21 Univ China Medical Pharmaceutical composition for inhibiting inflammation
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
US20150004219A1 (en) * 2012-02-02 2015-01-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Stable liposomes for drug delivery
DK2854769T3 (en) * 2012-07-05 2023-06-26 Taiwan Liposome Co Ltd METHODS OF TREATMENT OF ARTHRITIS
EP3062774A2 (en) * 2013-10-31 2016-09-07 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations

Also Published As

Publication number Publication date
EP3463304A4 (en) 2020-01-08
EP3463304A1 (en) 2019-04-10
WO2017203529A1 (en) 2017-11-30
CA3025208A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
IL263174A (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
HK1258588A1 (en) Compounds and formulations for treating ophthalmic diseases
IL254288B (en) C22-, c23- and c24-amino-carbonyl-oxy derivatives of bile acids and their use for treating tgr5-mediated diseases
HUE065662T2 (en) Compositions and methods relating to the treatment of diseases
IL255109A0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL246791A0 (en) Compositions and methods for treating ocular diseases
EP3319976A4 (en) Compositions and methods for treating lung diseases and lung injury
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL249098A0 (en) Methods and compositions for treating allergy and inflammatory diseases
HRP20181332T1 (en) Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
ZA202100703B (en) Compositions and methods for treating inflammasome related diseases or conditions
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
PL3319616T3 (en) Pectin compositions for preventing and treating inflammatory diseases
EP3265103A4 (en) Compositions and methods for treating ocular diseases
EP3581204A4 (en) Preventive and/or therapeutic agent for infectious diseases or inflammatory diseases
EP3362085A4 (en) Compositions and methods for the treatment of diseases involving mucin
EP3310338A4 (en) Compositions and methods for treating inflammatory disease or conditions
IL257689B (en) Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases
EP3277088A4 (en) Nanoparticle compositions and methods for treating or preventing tissue infections and diseases
WO2015003049A3 (en) Compositions and methods to treat inflammatory joint disease
EP3107998A4 (en) Compositions and methods for treating autoimmune and inflammatory diseases
EP3348279A4 (en) Medicinal composition for preventing or treating inflammatory respiratory disease
AU2015904201A0 (en) Compositions and methods for the treatment of diseases involving mucin
EP3247396A4 (en) Methods and compositions for the treatment of diseases and disorders